甲基(3R,5R)-5-甲基-3-哌啶羧酸酯 | 405513-10-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 甲基(3R,5R)-5-甲基-3-哌啶羧酸酯
• 英文名称: (3R,5R)-Methyl 5-methylpiperidine-3-carboxylate
• 英文别名: methyl (3R,5R)-5-methylpiperidine-3-carboxylate
• CAS: 405513-10-2
• 化学式: C₈H₁₅NO₂
• 分子量: 157.21
• InChiKey: HJPYJRXRHXOATI-RNFRBKRXSA-N

物化性质

• 沸点：
  205.9±33.0 °C(Predicted)
• 密度：
  0.982±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  11
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  38.3
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• Zwitterionic tachykinin receptor antagonists
  申请人：——

  公开号：US20020042431A1

  公开（公告）日：2002-04-11

  The present invention is directed to certain novel compounds represented by structural formula I: 1 or a pharmaceutically acceptable salt thereof, wherein R 3 , R 5 , R 6 , R 7 , R 8 , R 11 , R 12 R 13 , Q, W, X, Y and Z are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of psychiatric disorders including depression and anxiety.

  本发明涉及由结构式I：1所代表的某些新化合物或其药用可接受的盐，其中R3、R5、R6、R7、R8、R11、R12、R13、Q、W、X、Y和Z在此定义。该发明还涉及含有这些新化合物作为活性成分的药物配方，以及该新化合物及其配方在治疗某些疾病中的用途。本发明的化合物是催吐肽受体拮抗剂，可用于治疗包括抑郁症和焦虑症在内的精神障碍。
• ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS
  申请人：Merck & Co., Inc.

  公开号：EP1322596A1

  公开（公告）日：2003-07-02
• US6479518B2
  申请人：——

  公开号：US6479518B2

  公开（公告）日：2002-11-12
• [EN] ZWITTERIONIC TACHYKININ RECEPTOR ANTAGONISTS<br/>[FR] ANTAGONISTES ZWITTÉRIONIQUES DU RÉCEPTEUR DE LA TACHYKININE
  申请人：MERCK & CO INC

  公开号：WO2002024629A1

  公开（公告）日：2002-03-28

  The present invention is directed to certain novel compounds represented by structural formula (I), or a pharmaceutically acceptable salt thereof, wherein R?3, R5, R6, R7, R8, R11, R12, R13¿, Q, W, X, Y and Z are defined herein. The invention is also concerned with pharmaceutical formulations comprising these novel compounds as active ingredients and the use of the novel compounds and their formulations in the treatment of certain disorders. The compounds of this invention are tachykinin receptor antagonists and are useful in the treatment of psychiatric disorders including depression and anxiety.